Pharma / Biotech

Keytruda Gains 2 New First-Line Indications: NSCLC and RCC

The FDA approved pembrolizumab (Keytruda, Merck) for the first-line treatment of patients with stage III/IV non-small cell lung cancer who are not candidates for surgery or definitive chemoradiation. The agency also approved pembrolizumab in combination with the tyrosine kinase inhibitor axitinib (Inlyta, Pfizer) for the first-line treatment of patients with advanced renal cell carcinoma.

Source link

Related posts

ANTACID SOFT CHEW (Calcium Carbonate) Tablet, Chewable [Walgreen Co.]


AYGESTIN (Norethindrone Acetate) Tablet [Teva Women'S Health, Inc.]


ECONAZOLE NITRATE Cream [Teligent Pharma, Inc.]


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy